Patent expirations on blockbuster drugs threaten $440 billion in pharma revenues, with Merck-MSD and AbbVie most exposed
Executive summary: Patent expirations on best-selling drugs are expected to cost pharmaceutical companies $440 billion in lost revenue as competition from generics and biosimilars increases. This revenue erosion threatens the financial stability of major pharma firms and increases pressure to innovate or pursue M&A to replace declining income streams.
Who is involved: Pharmaceutical companies, particularly Merck-MSD and AbbVie, which are identified as most exposed due to their reliance on blockbuster drugs facing patent expiry.
Likely next: Accelerated investment in R&D, lifecycle extension strategies, and potential acquisitions to replenish pipelines amid looming generic competition.
The upcoming wave of patent expirations for top-selling pharmaceuticals is set to trigger significant revenue losses for drugmakers as generic and biosimilar competition enters the market. Merck-MSD and AbbVie are highlighted as particularly vulnerable due to their reliance on a concentrated portfolio of high-revenue drugs facing imminent exclusivity loss. This structural shift underscores the industry’s ongoing dependence on lifecycle management and new product pipelines to offset eroding revenues from aging assets.
Timeline
- — AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging (PR Newswire)
- — Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China (PR Newswire)
- — El fin de las patentes costará las farmacéuticas 440.000 millones (Expansión)
Analysis — what this means
Likely next events
- Major patent expiries for Humira (AbbVie) and Keytruda (Merck-MSD) biosimilars to enter market in 2027
- FDA expected to approve additional biosimilars for top 10 selling drugs by end of 2026
- Pharma companies to report Q3 2026 earnings with updated guidance on patent cliff impacts
Sectors affected
- Pharmaceuticals
- Biosimilars
- Generic drug manufacturing
Regulatory implications
- FDA continues accelerated approval pathway for biosimilars under Biosimilar Price Competition and Innovation Act
- EU extends market exclusivity protections for certain orphan drugs, delaying competition
- Inflation Reduction Act provisions allow Medicare negotiation on select drugs post-patent expiry
Historical parallels
- Lipitor patent expiry in 2011 led to >80% revenue loss for Pfizer within two years
- Plavix generic entry in 2012 reduced Bristol-Myers Squibb’s annual sales by $3B+
- Singulair patent loss in 2012 caused Merck to lose ~$4B in annual revenue
Sources
- El fin de las patentes costará las farmacéuticas 440.000 millones — Expansión
- AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging — PR Newswire
- Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China — PR Newswire
Related cases
- Approval of Merck's oral PCSK9 inhibitor LIPFENDRA and emerging oral competitors signal a high‑growth phase for the PCSK9 inhibitor market
- Pharma deal volume jumps 70% to €343.5bn Jan‑Jul 2026, led by Lilly, BMS, AbbVie and GSK
- AbbVie seeks EMA approval for subcutaneous risankizumab induction in Crohn’s disease, expanding its immunology portfolio
- AbbVie’s neuroscience division is projected to generate $12.7 billion in sales this year, marking a key shift away from its Humira‑centric model
- Merck raises full-year guidance after Q2 beat driven by AI and oncology strength
- Healthcare stocks become a safe haven as investors exit tech